Filing Flows › Comparisons › SPRO vs COYA
Spero Therapeutics vs Coya Therapeutics: SPRO and COYA compared
Spero Therapeutics is the larger company: $258K of revenue in its latest quarter (Q1 2026) against $244K for Coya Therapeutics (Q2 2026). Coya Therapeutics is growing faster (+49% against -96% a year earlier).
Where the money goes: SPRO and COYA
Spero Therapeutics (SPRO) · Q1 2026
Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year), net loss $7.2M, operating cash flow $15.9M. The chart follows the revenue to costs, profit and cash.
Coya Therapeutics (COYA) · Q2 2026
Coya Therapeutics, Q2 2026: revenue $244K (+49% year over year), net loss $6.6M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
| Spero Therapeutics (SPRO) | Coya Therapeutics (COYA) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $258K | $244K |
| Revenue growth, Y/Y | -96% | +49% |
| Operating margin | n/m | n/m |
| Net earnings | −$7.2M | −$6.6M |
| Operating cash flow | $15.9M | −$7.4M |
Questions
Which is bigger, Spero Therapeutics or Coya Therapeutics?
Spero Therapeutics is the larger company: $258K of revenue in its latest quarter (Q1 2026) against $244K for Coya Therapeutics (Q2 2026).
Is Spero Therapeutics or Coya Therapeutics growing faster?
Coya Therapeutics is growing faster (+49% against -96% a year earlier).
More: Spero Therapeutics earnings · how Spero Therapeutics makes money · Coya Therapeutics earnings · how Coya Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 13, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.